TCT 2024 Late-Breaking Science Collection

Published: 17 October 2024

  • Views:

    Views Icon 2428
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep informed with our video collection unveiling data from the Transcatheter Cardiovascular Therapeutics Conference in Washington. With expert insights on late-breaking trials and critical findings, you won't want to miss our #TCT24 coverage.

  • For practice-focused reviews of the most anticipated trials, watch our recurring View From the Thoraxcenter series, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Our short Expert Interviews with select faculty offer focused data analysis and take-home messages for practice.
  • To delve deeper into insights on the most pertinent trials, catch our Highlights.

Dive into the latest cardiology research with our upcoming TCT Conference coverage.

About the episode

TCT Conference 24 - Two-year outcomes of CLASP IID shows that the Edwards PASCAL system was noninferior to the Abbott Mitraclip system in transcatheter mitral valve repair for mitral regurgitation.

Dr Firas Zahr (Oregon Health and Science University, US) joins us onsite at TCT Conference to discuss the outcomes from the CLASP IID 2 Year RCT and Registry (NCT02371512; Edwards Lifesciences).

CLASP IID 2 is a multicenter, randomised, controlled trial investigating the use of the Edwards PASCAL system for transcatheter mitral edge-to-edge repair (TEER) in patients with moderate-to-severe mitral regurgitation (MR). 300 patients were enrolled in the study and were followed-up at discharge, 30 days, 6 months, and annually through 5 years.

Two-year findings showed the Edwards PASCAL system demonstrated favorable survival rates with significant and consistent improvements in functional status and quality of life for MR patients, sustained MR reduction, and significant and durable ventricular remodeling.

Interview Questions:
1.    What is the reasoning behind this study?
2.    What was the study design and patient population?
3.    What were the key findings?
4.     Were there any surprising or unexpected results?
5.    What further research is needed, and what are the next steps?

Recorded on-site at TCT Conference in Washington, 24

Editors: Yazmin Sadik, Jordan Rance
Videographers:

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Firas Zahr

Firas Zahr

Director of Interventional Cardiology and Associate Professor of Medicine

Dr Firas Zahr is an Associate Professor of Medicine in the Division of Cardiovascular Medicine at Oregon Health and Science University. At the same institution, he is the Director of Interventional Cardiology and Co-Director of the Structural Heart Disease program.

Dr Zahr earned his MD from the University of Damascus in 2002 and has been in practice for more than 20 years. He further specialised with an Interventional Cardiology Structural Fellowship at the University of Pittsburgh Medical Center.

He is a Fellow of the American College of Cardiology, and his research focuses on cardiac catheterization, transcatheter valve therapies and interventional cardiology. Alongside his investigations, Dr Zahr has written over a hundred publications in peer reviewed journals focusing on valvular heart disease management.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.